{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:05:28Z","timestamp":1753887928490,"version":"3.41.2"},"reference-count":40,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Youth Foundation of Beijing Shijitan Hospital Affiliated to Capital Medical University","award":["2022-q14"],"award-info":[{"award-number":["2022-q14"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz J Med Biol Res"],"abstract":"<jats:p>Immune checkpoint blockade with anti-programmed cell death protein 1 (PD-1) antibody has become a hot topic for the treatment of human malignancies. Here, we aimed to investigate whether the percentage of PD-1 in CD8+ tumor-infiltrating lymphocytes correlates with the progression of colonic-derived peritoneal adenocarcinoma (PA). Peripheral blood and tissue samples from 40 patients with colonic-derived PA were collected and subjected to multicolor flow cytometry analysis of the percentage of peripheral PD-1+CD8+ T cells. The multiple immunofluorescence method was used to detect the positive percentages of PD-1 and CD8 in the tissues. The enrolled patients were divided into groups by recurrence interval (less than 6 months, greater than two years) and differentiation grade (low, well\/moderate). In the colonic-derived PA tissues, the percentages of cells positive for PD-1, CD8, and PD-1+CD8+ were higher in the paracancer tissues compared with cancerous tissues. PD-1+CD8+ T cells had an increased presence in peripheral blood than in tissues. Our data also indicated that colonic-derived PA patients with less than a six-month recurrence interval presented higher levels of PD-1 in CD8+ tumor-infiltrating lymphocytes in than the two-year recurrence group. The level of PD-1+CD8+T cells in the tissue correlated with the clinical outcome of colonic-derived PA. Higher percentages of PD-1+CD8+T cells correlated with a shorter progression-free survival (PFS). PD-1 in CD8+ tumor-infiltrating lymphocytes may have a good predictive value for immunotherapy of colonic-derived PA and act as the prognostic factor for PFS.<\/jats:p>","DOI":"10.1590\/1414-431x2025e14467","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T22:23:41Z","timestamp":1744842221000},"source":"Crossref","is-referenced-by-count":0,"title":["PD-1 involvement in CD8+ tumor-infiltrating lymphocytes in patients with colonic-derived peritoneal adenocarcinoma"],"prefix":"10.1590","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9418-2639","authenticated-orcid":false,"given":"Huihui","family":"Hu","sequence":"first","affiliation":[{"name":"Capital Medical University,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5166-6804","authenticated-orcid":false,"given":"Man","family":"Zhang","sequence":"additional","affiliation":[{"name":"Capital Medical University,  China; Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics,  China; Peking University Ninth School of Clinical Medicine,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2025]]},"reference":[{"issue":"38","key":"ref1","doi-asserted-by":"crossref","first-page":"61336","DOI":"10.18632\/oncotarget.11038","article-title":"Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer","volume":"7","author":"Auer K","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"ref2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian SL","year":"2023","journal-title":"Cancer Cell"},{"issue":"21","key":"ref3","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad G","year":"2021","journal-title":"Cell"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","article-title":"CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases","volume":"74","author":"Li Y","year":"2025","journal-title":"Gut"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.cell.2017.11.006","article-title":"A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T Cells","volume":"171","author":"Singer M","year":"2017","journal-title":"Cell"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.2147\/CMAR.S185176","article-title":"The clinical promise of immunotherapy in triple-negative breast cancer","volume":"10","author":"Vikas P","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1+CD8+Tcell pool with predictive potential 2018; in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen DS","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12967-023-03912-2","article-title":"High proportion of circulating CD8+CD28- senescent T cells are an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy","volume":"21","author":"Xu X","year":"2023","journal-title":"J Transl Med"},{"issue":"18","key":"ref9","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","article-title":"Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal t-cell populations when combined with PD-1 blockade","volume":"23","author":"Dovedi SJ","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti SC","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1111\/cas.13723","article-title":"PD-1+TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer","volume":"109","author":"Nakano M","year":"2018","journal-title":"Cancer Sci"},{"issue":"8","key":"ref12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into cell exhaustion","volume":"15","author":"Wherry EJ","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1158\/0008-5472.CAN-16-0274","article-title":"Tim-3 expression on tumor-infiltrating PD-1(+) CD8(+) T cells correlates with poor clinical outcome in renal carcinoma","volume":"77","author":"Granier C","year":"2017","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1: PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan K","year":"2016","journal-title":"Front Immunol"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","article-title":"Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure)","volume":"27","author":"Kim JM","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi M","year":"2022","journal-title":"Mol Cancer"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12885-023-10752-2","article-title":"Peripheral PD-1 and Tim-3 Percentages are associated with primary sites and pathological types of peritoneal neoplasms","volume":"23","author":"Hu H","year":"2023","journal-title":"BMC Cancer"},{"issue":"8","key":"ref18","doi-asserted-by":"crossref","first-page":"e0221301","DOI":"10.1371\/journal.pone.0221301","article-title":"Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade","volume":"14","author":"Bochem J","year":"2019","journal-title":"PloS One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang X","year":"2016","journal-title":"Onco Targets Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5294043","DOI":"10.1155\/2020\/5294043","article-title":"Prognostic impact of PD-1 and Tim-3 expression in tumor tissue in stage I-III colorectal cancer","volume":"2020","author":"Kuai W","year":"2020","journal-title":"Biomed Res Int"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e000911","DOI":"10.1136\/jitc-2020-000911","article-title":"Tim-3 finds its place in the cancer immunotherapy landscape","volume":"8","author":"Acharya N","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida Y","year":"1992","journal-title":"EMBO J"},{"issue":"26","key":"ref23","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian SL","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"e000255","DOI":"10.1136\/esmoopen-2017-000255","article-title":"Targeting immune checkpoints in breast cancer: an update of early results","volume":"2","author":"Solinas C","year":"2017","journal-title":"ESMO Open"},{"issue":"19","key":"ref25","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst AO","year":"2017","journal-title":"Proc Nat Acad Sci USA"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1038\/s41598-021-85966-0","article-title":"PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome","volume":"11","author":"Bekos C","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and Tim-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang R","year":"2021","journal-title":"Nat Commun"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan D","year":"2011","journal-title":"Cell"},{"issue":"8","key":"ref29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00262-024-03721-6","article-title":"Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma","volume":"73","author":"Sun YT","year":"2024","journal-title":"Cancer Immunol Immunother"},{"issue":"21","key":"ref30","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the orient-16 randomized clinical trial","volume":"330","author":"Xu J","year":"2023","journal-title":"JAMA"},{"issue":"10294","key":"ref31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian YY","year":"2021","journal-title":"Lancet"},{"issue":"26","key":"ref32","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer JR","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng L","year":"2014","journal-title":"J Clin Invest"},{"issue":"4","key":"ref34","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.immuni.2018.03.018","article-title":"Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells","volume":"48","author":"Li J","year":"2018","journal-title":"Immunity"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/bjc.2017.369","article-title":"Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer","volume":"117","author":"Seo AN","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12943-016-0539-x","article-title":"Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer","volume":"15","author":"Li Y","year":"2016","journal-title":"Mol Cancer"},{"issue":"40","key":"ref37","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.3748\/wjg.v29.i40.5566","article-title":"Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment","volume":"29","author":"Hoshimoto A","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"1","key":"ref38","first-page":"1","article-title":"Upregulation of TIM-3 and PD-1 on CD4+ and CD8+ T cells associated with dysfunction of cell-mediated immunity after colorectal cancer operation","volume":"55","author":"Arai Y","year":"2012","journal-title":"Yonago Acta Med"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4103\/ijpm.ijpm_90_21","article-title":"Molecular subtypes of invasive breast carcinoma of no special type, their correlation with histopathological features, Ki 67 index and tumor budding: A retrospective comparative study","volume":"65","author":"Radhakrishnan N","year":"2022","journal-title":"Indian J Pathol Microbiol"},{"issue":"9","key":"ref40","first-page":"987","article-title":"SPHK2 protein expression, Ki-67 index and infiltration of tumor-associated macrophages (TAMs) in human glioma","volume":"33","author":"Liu J","year":"2018","journal-title":"Histol Histopathol"}],"container-title":["Brazilian Journal of Medical and Biological Research"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0100-879X2025000100633&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T22:23:46Z","timestamp":1744842226000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-879X2025000100633&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":40,"alternative-id":["S0100-879X2025000100633"],"URL":"https:\/\/doi.org\/10.1590\/1414-431x2025e14467","relation":{},"ISSN":["1414-431X","0100-879X"],"issn-type":[{"type":"electronic","value":"1414-431X"},{"type":"print","value":"0100-879X"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e14467"}}